Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation

Arthritis and Rheumatism

Volumn 52, Issue 9, 2005, Pages 2594-2598

  Felson, David T ^a,c   Cummings, Steven R ^b  

^a BOSTON UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; LEUPRORELIN; TAMOXIFEN;

ARTHRALGIA; ESTROGEN ACTIVITY; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; HUMAN; INFLAMMATION; MENOPAUSE; NOCICEPTION; PRIORITY JOURNAL; REVIEW;

AROMATASE; AROMATASE INHIBITORS; ARTHRALGIA; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; SYNDROME;

EID: 25444478032     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21364     Document Type: Review

References (44)

1. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer [review]. J Clin Oncol 2001;19:881-94.
2. Brodie AM, Wing LY, Goss P, Dowsett M, Coombes RC. Aromatase inhibitors and their potential clinical significance. J Steroid Biochem 1986;25:859-65.
3. Geisler J, Anker G, Dowsett M, Lonning PE. Letrozole suppresses plasma estrogen levels in postmenopausal breast cancer patients more completely than anastrozole [abstract]. Proc Am Soc Clin Oncol 2000;19:102a.
4. Geisler J, King N, Anker G, Ornati G, Di Salle E, Lonning PE, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4:2089-93.
5. Lonning PE. Pharmacology of new aromatase inhibitors. Breast 1996;5:206-8.
6. Dawson-Basoa ME, Gintzler AR. Estrogen and progesterone activate spinal κ-opiate receptor analgesic mechanisms. Pain 1996;64:169-77.
7. Kidd BL, Photiou A, Inglis JJ. The role of inflammatory mediators on nociception and pain in arthritis [review]. Novartis Found Symp 2004;260:122-33.
8. Schaible HG. Spinal mechanisms contributing to joint pain [review]. Novartis Found Symp 2004;260:4-22.
9. Pacifici R. Cytokines, estrogen, and postmenopausal osteoporosis: the second decade. Endocrinology 1998;139:2659-61.
10. Maret A, Clamens S, Delrieu I, Elhage R, Arnal JF, Bayard F. Expression of the interleukin-6 gene is constitutive and not regulated by estrogen in rat vascular smooth muscle cells in culture. Endocrinology 1999;140:2876-82.
11. Salem ML. Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production [review]. Curr Drug Targets Inflamm Allergy 2004;3:97-104.
12. D'Agostino P, Milano S, Barbera C, Di Bella G, La Rosa M, Ferlazzo V, et al. Sex hormones modulate inflammatory mediators produced by macrophages. Ann N Y Acad Sci 1999;876:426-9.
13. Vegeto E, Bonincontro C, Pollio G, Sala A, Viappiani S, Nardi F, et al. Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. J Neurosci 2001;21:1809-18.
14. Blomqvist A. Sex hormones and pain: a new role for brain aromatase? [review]. J Comp Neurol 2000;423:549-51.
15. Flores CA, Shughrue P, Petersen SL, Mokha SS. Sex-related differences in the distribution of opioid receptor-like 1 receptor mRNA and colocalization with estrogen receptor mRNA in neurons of the spinal trigeminal nucleus caudalis in the rat. Neuroscience 2003;118:769-78.
16. Eckersell CB, Popper P, Micevych PE. Estrogen-induced alteration of μ-opioid receptor immunoreactivity in the medial preoptic nucleus and medial amygdala. J Neurosci 1998;18:3967-76.
17. Evrard H, Baillien M, Foidart A, Absil P, Harada N, Balthazart J. Localization and controls of aromatase in the quail spinal cord. J Comp Neurol 2000;423:552-64.
18. Giamberardino MA, Berkley KJ, Iezzi S, de Bigontina P, Vecchiet L. Pain threshold variations in somatic wall tissues as a function of menstrual cycle, segmental site and tissue depth in nondysmenorrheic women, dysmenorrheic women and men. Pain 1997;71:187-97.
19. Fillingim RB, Ness TJ. Sex-related hormonal influences on pain and analgesic responses [review]. Neurosci Biobehav Rev 2000;24:485-501.
20. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
21. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-61.
22. Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:3357-66.
23. Goss PE, Winer EP, Tannock IF, Schwartz LH. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. J Clin Oncol 1999;17:52-63.
24. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [published erratum appears in N Engl J Med 2004;351:2461]. N Engl J Med 2004;350:1081-92.
25. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al, and the ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial [published erratum appears in Lancet 2002;360:1520]. Lancet 2002;359:2131-9.
26. Jinks C, Jordan K, Croft P. Measuring the population impact of knee pain and disability with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Pain 2002;100:55-64.
27. Donnellan PP, Douglas SL, Cameron DA, Leonard RC. Aromatase inhibitors and arthralgia [letter]. J Clin Oncol 2001;19:2767.
28. Friedman AJ, Juneau-Norcross M, Rein MS. Adverse effects of leuprolide acetate depot treatment. Fertil Steril 1993;59:448-50.
29. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
30. Croft P, Rigby AS, Boswell R, Schollum J, Silman A. The prevalence of chronic widespread pain in the general population. J Rheumatol 1993;20:710-3.
31. Cecil RL, Archer BH. Arthritis of the menopause. JAMA 1925;84:75-9.
32. Ho SC, Chan SG, Yip YB, Cheng A, Yi Q, Chan C. Menopausal symptoms and symptom clustering in Chinese women. Maturitas 1999;33:219-227.
33. Randolph JF Jr, Sowers M, Bondarenko IV, Harlow SD, Luborsky JL, Little RJ. Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age. J Clin Endocrinol Metab 2004;89:1555-61.
34. Cauley JA, Gutai JP, Kuller LH, LeDonne D, Powell JG. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989;129:1120-31.
35. Greendale GA, Reboussin BA, Hogan P, Barnabei VM, Shumaker S, Johnson S, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998;92:982-8.
36. Nevitt MC, Felson DT, Williams EN, Grady D, for the Heart and Estrogen/Progestin Replacement Study Research Group. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: the Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2001;44:811-8.
37. Musgrave DS, Vogt MT, Nevitt MC, Cauley JA. Back problems among postmenopausal women taking estrogen replacement therapy: the study of osteoporotic fractures. Spine 2001;26:1606-12.
38. Macfarlane TV, Blinkhorn A, Worthington HV, Davies RM, Macfarlane GJ. Sex hormonal factors and chronic widespread pain: a population study among women. Rheumatology (Oxford) 2002;41:454-7.
39. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention [review]. Arthritis Rheum 1998;41:1343-55.
40. Felson DT, Nevitt MC. Estrogen and osteoarthritis: how do we explain conflicting study results? [review]. Prev Med 1999;28:445-8.
41. Ham KD, Loeser RF, Lindgren BR, Carlson CS. Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis Rheum 2002;46:1956-64.
42. Cauley JA, Kwoh CK, Egeland G, Nevitt MC, Cooperstein L, Rohay J, et al. Serum sex hormones and severity of osteoarthritis of the hand. J Rheumatol 1993;20:1170-5.
43. Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002;46:625-31.
44. Cutolo M. Sex hormone adjuvant therapy in rheumatoid arthritis [review]. Rheum Dis Clin North Am 2000;26:881-95.